Delivery Matters: In Early Studies, DPX Technology Allows V

Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent immune responses.

Related Keywords

New York , United States , Stonegate , American , Andrew Hall , Jeremy Graff , Cargo In Oil , American Society Of Hematology Annual Meeting , That Persist , Evidence Based Oncology , American Society , Hematology Annual Meeting , Accessed March , Dpx , Cancer Vaccines , Immuno Oncology , Immunotherapy ,